CD19 and infection: Overall, across the largest observational studies of infectious risk, infections were reported in 19–69% of patients after CD19-directed CAR T-cell therapy (2, 5), and in 42%-69% of patients after BCMA-directed CAR T-cell therapy; life-threatening infections are infrequently reported (2).